Interplay effects in highly modulated stereotactic body radiation therapy lung cases treated with volumetric modulated arc therapy. Purpose: To evaluate the influence of tumor motion on dose delivery in highly modulated stereotactic body radiotherapy (SBRT) of lung cancer using volumetric modulated arc therapy (VMAT). Methods: 4D-CT imaging data of the quasar respiratory phantom were acquired, using a GE Lightspeed 16-slice CT scanner, while the phantom reproduced patient specific respiratory traces. Flattening filter-free (FFF) dual-arc VMAT treatment plans were created on the acquired images in Pinnacle 3 treatment planning system. Each plan was generated with varying levels of complexity characterized by the modulation complexity score. Static and dynamic measurements were delivered to Gaf-Chromic EBT3 film inside the respiratory phantom using an Elekta Versa HD linear accelerator. The treatment prescription was 10 Gy per fraction for 5 fractions. Comparisons of the planned and delivered dose distribution were performed using Radiological Imaging Technology (RIT) software. Results: For the motion amplitudes and periods studied, the interplay effect is insignificant to the GTV coverage. The mean dose deviations between the planned and delivered dose distribution never went below −2.00% and a minimum dose difference of −5.05% was observed for a single fraction. However for amplitude of 2 cm, the dose error could be as large as 20.00% near the edges of the PTV at increased levels of complexity. Additionally, the modulation complexity score showed an ability to provide information related to dose delivery. A correlation value (R) of 0.65 was observed between the complexity score and the gamma passing rate for GTV coverage. Conclusions: As expected, respiratory motion effects are most evident for large amplitude respirations, complex fields, and small field margins. However, under all tested conditions target coverage was maintained.
Purpose: Determine if a uniform planning target volume (PTV) margin can be used for intensity modulated proton therapy (IMPT) of centrally located pediatric brain tumors and determine the most appropriate value. Methods: Treatment planning data from three pediatric patients with centrally located brain tumors were used in this study. For each patient, two IMPT plan types, a 3 field multi‐field‐optimized (MFO) and a 3 field single‐field‐optimized (SFO), and a 5 field IMRT plan were created for 7 uniform PTV margins that ranged from 0 to 10mm. The IMPT plans did not use robust optimization. For all plan types, the target coverage was held constant (98% of CTV received 54Gy and 95% of PTV received >53Gy) and normal tissue doses were minimized. Four error types, each with numerous variations, were simulated and their effect were recorded. The four error types were: systematic plan position error, systematic field position error, systematic range error, and random position error. Results: Regarding normal tissues, there was no notable difference between MFO and SFO, both were substantially better than IMRT, e.g. mean cochlea dose was 14Gy for IMRT with 3mm margin and 5Gy for the IMPT plans. In general, smaller margins gave better normal tissue sparring. For both IMPT plan types and IMRT, PTV margins less than 3mm lead to target coverage deficits under the various errors. For position errors, the IMPT and IMRT plans gave similar results as a function of margin size. For density and systematic field errors, the SFO plans maintained target coverage better than MFO. Conclusions: A uniform PTV margin is not suitable for MFO planning. However, a uniform PTV margin of 3mm is appropriate for SFO planning when considering the above uncertainties (excluding large errors). At 3mm, which is also required for IMRT, the SFO plans had superior normal tissue sparing. Varian Medical Systems
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.